NASDAQ:MEIP MEI Pharma - MEIP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.33 -0.01 (-1.53%) (As of 02/3/2023 12:33 PM ET) Add Compare Share Share Today's Range$0.31▼$0.3350-Day Range$0.22▼$0.4152-Week Range$0.21▼$2.21Volume132,408 shsAverage Volume515,296 shsMarket Capitalization$43.74 millionP/E RatioN/ADividend YieldN/APrice Target$2.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability MEI Pharma MarketRank™ ForecastAnalyst RatingHold2.17 Rating ScoreUpside/Downside763.7% Upside$2.86 Price TargetShort InterestHealthy3.42% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment-0.33Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.52) to ($0.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector453rd out of 1,029 stocksPharmaceutical Preparations Industry217th out of 501 stocks 3.1 Analyst's Opinion Consensus RatingMEI Pharma has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.86, MEI Pharma has a forecasted upside of 763.7% from its current price of $0.33.Amount of Analyst CoverageMEI Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.42% of the outstanding shares of MEI Pharma have been sold short.Short Interest Ratio / Days to CoverMEI Pharma has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MEI Pharma has recently increased by 19.37%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMEI Pharma does not currently pay a dividend.Dividend GrowthMEI Pharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMEI Pharma has received a 73.99% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for MEI Pharma is -0.85. Previous Next 1.5 News and Social Media Coverage News SentimentMEI Pharma has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MEI Pharma this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for MEIP on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.MarketBeat Follows8 people have added MEI Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MEI Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.16% of the stock of MEI Pharma is held by insiders.Percentage Held by InstitutionsOnly 35.74% of the stock of MEI Pharma is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for MEI Pharma are expected to grow in the coming year, from ($0.52) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MEI Pharma is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MEI Pharma is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMEI Pharma has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MEI Pharma (NASDAQ:MEIP) StockMEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its products include Zandelisib, Voruciclib, and ME-344. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.Read More Receive MEIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address MEIP Stock News HeadlinesJanuary 30, 2023 | americanbankingnews.comMEI Pharma (NASDAQ:MEIP) Research Coverage Started at StockNews.comJanuary 29, 2023 | americanbankingnews.comMEI Pharma (NASDAQ:MEIP) Stock Price Crosses Below 200-Day Moving Average of $0.40February 3, 2023 | Investing Trends (Ad)Apple, Amazon, and Walmart are Investing in Solar EnergyThe global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.January 24, 2023 | americanbankingnews.comMEI Pharma, Inc. (NASDAQ:MEIP) Given Average Recommendation of "Hold" by AnalystsDecember 6, 2022 | seekingalpha.comMEI Pharma slumps on ending lead drug development ex-Japan, analysts downgrade stockDecember 6, 2022 | finance.yahoo.comMEI Pharma Announces Adjournment of Annual Meeting of StockholdersDecember 6, 2022 | marketwatch.comMEI Pharma Shares Dive 34% on Discontinued Development of Zandelisib Outside of JapanDecember 5, 2022 | finance.yahoo.comMEI Pharma Initiates Strategic RealignmentFebruary 3, 2023 | PressReach (Ad)Biotech Stock AlertRead Small Pharma's depression clinical trial results.November 20, 2022 | finance.yahoo.comMEI Pharma First Quarter 2023 Earnings: Beats ExpectationsNovember 19, 2022 | finance.yahoo.comAnalysts Just Published A Bright New Outlook For MEI Pharma, Inc.'s (NASDAQ:MEIP)November 18, 2022 | finance.yahoo.comKyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in JapanNovember 15, 2022 | finance.yahoo.comMEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational HighlightsNovember 15, 2022 | finance.yahoo.comMEI Pharma, Inc. (MEIP) Reports Q1 Loss, Lags Revenue EstimatesNovember 7, 2022 | finance.yahoo.comWe're Keeping An Eye On MEI Pharma's (NASDAQ:MEIP) Cash Burn RateNovember 3, 2022 | finance.yahoo.comMEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022September 25, 2022 | au.finance.yahoo.comMEI Pharma, Inc. (MEIP)September 22, 2022 | finance.yahoo.comMEI Pharma Announces Changes to Board of DirectorsSeptember 17, 2022 | benzinga.com1MEIP : Looking Into MEI Pharma's Return On Capital EmployedSeptember 9, 2022 | seekingalpha.comMEI Pharma stock trades higher as FY22 revenue grows 17%September 9, 2022 | finance.yahoo.comEdited Transcript of MEIP.OQ earnings conference call or presentation 8-Sep-22 9:00pm GMTSeptember 9, 2022 | seekingalpha.comMEI Pharma, Inc. (MEIP) Q4 2022 Earnings Call TranscriptSeptember 8, 2022 | finance.yahoo.comMEI Pharma Reports Fiscal Year 2022 Results and Operational HighlightsSeptember 7, 2022 | msn.com1MEIP : Earnings Outlook For MEI PharmaSeptember 6, 2022 | finance.yahoo.comMEI Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022September 1, 2022 | finance.yahoo.comMEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Update on September 8, 2022August 25, 2022 | seekingalpha.comGreenWood Investors Second Quarter 2022 LetterSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MEIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address MEIP Company Calendar Last Earnings11/14/2022Today2/03/2023Next Earnings (Estimated)2/09/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MEIP Previous SymbolNASDAQ:MSHL CUSIPN/A CIK1262104 Webwww.meipharma.com Phone(858) 369-7100Fax302-655-5049Employees76Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.86 High Stock Price Forecast$5.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+770.5%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,450,000.00 Net Margins-98.17% Pretax Margin-111.46% Return on Equity-115.15% Return on Assets-35.67% Debt Debt-to-Equity RatioN/A Current Ratio6.35 Quick Ratio6.35 Sales & Book Value Annual Sales$40.70 million Price / Sales1.07 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book0.84Miscellaneous Outstanding Shares133,260,000Free Float125,052,000Market Cap$43.74 million OptionableOptionable Beta0.97 Key ExecutivesDaniel P. GoldPresident, Chief Executive Officer & DirectorDavid M. UrsoChief Operating Officer & General CounselBrian G. DrazbaChief Financial Officer & SecretaryRichard G. GhalieChief Medical OfficerBenjamin CadieuxVice President-Medical AffairsKey CompetitorsAcurx PharmaceuticalsNASDAQ:ACXPMonopar TherapeuticsNASDAQ:MNPREquilliumNASDAQ:EQFSD PharmaNASDAQ:HUGEEledon PharmaceuticalsNASDAQ:ELDNView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 322,969 shares on 11/15/2022Ownership: 5.755%Carlson Capital L PBought 50,000 shares on 11/15/2022Ownership: 0.863%Two Sigma Investments LPBought 127,046 shares on 11/15/2022Ownership: 0.284%Zacks Investment ManagementBought 109,819 shares on 11/14/2022Ownership: 0.082%Annandale Capital LLCBought 100,000 shares on 11/14/2022Ownership: 0.075%View All Institutional Transactions MEIP Stock - Frequently Asked Questions Should I buy or sell MEI Pharma stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MEIP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEIP, but not buy additional shares or sell existing shares. View MEIP analyst ratings or view top-rated stocks. What is MEI Pharma's stock price forecast for 2023? 6 equities research analysts have issued 1-year target prices for MEI Pharma's shares. Their MEIP share price forecasts range from $1.00 to $5.00. On average, they predict the company's share price to reach $2.86 in the next year. This suggests a possible upside of 763.7% from the stock's current price. View analysts price targets for MEIP or view top-rated stocks among Wall Street analysts. How have MEIP shares performed in 2023? MEI Pharma's stock was trading at $0.2436 at the beginning of the year. Since then, MEIP stock has increased by 35.8% and is now trading at $0.3308. View the best growth stocks for 2023 here. Are investors shorting MEI Pharma? MEI Pharma saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 4,560,000 shares, an increase of 19.4% from the December 31st total of 3,820,000 shares. Based on an average daily trading volume, of 1,270,000 shares, the days-to-cover ratio is presently 3.6 days. View MEI Pharma's Short Interest. When is MEI Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023. View our MEIP earnings forecast. How were MEI Pharma's earnings last quarter? MEI Pharma, Inc. (NASDAQ:MEIP) announced its quarterly earnings data on Monday, November, 14th. The company reported ($0.13) EPS for the quarter, hitting analysts' consensus estimates of ($0.13). The business had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.75 million. MEI Pharma had a negative trailing twelve-month return on equity of 115.15% and a negative net margin of 98.17%. What other stocks do shareholders of MEI Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), OPKO Health (OPK), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD). What is MEI Pharma's stock symbol? MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP." Who are MEI Pharma's major shareholders? MEI Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of MEI Pharma? Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MEI Pharma's stock price today? One share of MEIP stock can currently be purchased for approximately $0.33. How much money does MEI Pharma make? MEI Pharma (NASDAQ:MEIP) has a market capitalization of $44.08 million and generates $40.70 million in revenue each year. The company earns $-54,450,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. How can I contact MEI Pharma? MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.meipharma.com. The company can be reached via phone at (858) 369-7100, via email at investor@meipharma.com, or via fax at 302-655-5049. This page (NASDAQ:MEIP) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.